Research Library › Neuropeptides
Dihexa is a synthetic, chemically modified dipeptide analog derived from the hexapeptide angiotensin IV, built on a tyrosine–isoleucine core with a hexanoyl cap and a 6-aminohexanoic amide tail. It was developed by Joseph Harding, John Wright and colleagues at Washington State University and first described in detail in 2013. As of October 2026 it is not FDA-approved; dihexa acetate was removed from FDA’s Category 2 compounding list in April 2026 and awaits FDA advisory committee review expected before the end of February 2027.
Key facts
| Type | Synthetic modified dipeptide (small peptide analog), formula C27H44N4O5 |
|---|---|
| Derived from | Angiotensin IV (Val-Tyr-Ile-His-Pro-Phe), via the analog norleucine-1-angiotensin IV |
| Chemical name | N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; code PNB-0408 |
| First described | Patent priority 2011; detailed paper January 2013 |
| Developed by | Joseph W. Harding, John W. Wright and colleagues, Washington State University |
| Designed target | Proposed to interact with the hepatocyte growth factor (HGF)/c-Met system in preclinical studies |
| Regulatory status (Oct 2026) | Not FDA-approved; removed from Category 2 in April 2026; FDA PCAC review expected before end of February 2027, no date set |
Who developed it
Dihexa came out of the laboratory of Joseph W. Harding and John W. Wright at Washington State University (WSU) in Pullman, which ran a long-standing research program on angiotensin IV and its analogs. A WSU patent filed with a 2011 priority date, naming Harding, Wright, Caroline Benoist, Leen Kawas and Gary Wayman as inventors, covers a family of hepatocyte growth factor mimics that includes the compound [1].
Harding and Wright co-founded a spin-out company, M3 Biotechnology, to develop the work; the company later renamed itself Athira Pharma [2].
Structure and design
Angiotensin IV is a six-amino-acid fragment of the angiotensin system. The WSU group took an earlier analog, norleucine-1-angiotensin IV, and identified its first three residues as a core to modify. In a 2013 paper McCoy and colleagues described changing both ends of the chain to resist breakdown by enzymes, then making the molecule more fat-soluble and less able to form hydrogen bonds, with the stated aim of better crossing biological barriers [3].
The lead compound from that work is dihexa: a tyrosine–isoleucine dipeptide with a hexanoic acid group on the N-terminus and a 6-aminohexanoic amide on the C-terminus [3]. Its formula is C27H44N4O5. The group proposed, from cell and animal studies, that it acts on the hepatocyte growth factor (HGF)/c-Met receptor system [1, 4]. This remains a proposed mechanism.
Research history and research-integrity notices
- 2011: Priority date of the WSU patent on HGF mimics [1]
- 2013: McCoy et al. describe dihexa in detail; WSU patent US 8,598,118 granted 3 December [1, 3]
- 2014: Benoist et al. link the group’s angiotensin IV analogs to the HGF/c-Met system [4]
- 2021: JPET issues expressions of concern on four papers from the group [2, 5]
- 2025: The 2014 Benoist paper is listed as retracted in PubMed [6]
In September 2021 the Journal of Pharmacology and Experimental Therapeutics (JPET) placed expressions of concern on four papers from the WSU group, including the 2013 dihexa paper and the 2014 HGF/c-Met paper, citing possible image manipulation and awaiting a WSU inquiry [2, 5]. The 2014 paper has since been retracted [6]. Readers should weigh the early literature on dihexa with these notices in mind.
Regulatory status as of October 2026
Dihexa is not approved as a drug by the FDA or, as far as published records show, by any other regulator. Dihexa acetate had been placed in FDA’s Category 2 of bulk substances nominated for compounding, meaning substances that raise significant safety concerns. In April 2026 the FDA announced it would remove dihexa acetate and 11 other peptides from Category 2 after the nominations were withdrawn [7].
The FDA said dihexa acetate, along with LL-37, injectable GHK-Cu, PEG-MGF and Melanotan II, would go to its Pharmacy Compounding Advisory Committee (PCAC) at a second meeting before the end of February 2027 [7, 8]. As of mid-October 2026 no date or public docket had been set, and dihexa is not on the 503A bulks list [8]. Removal from Category 2 is not an approval and does not by itself make the substance eligible for compounding [7].
About this reference page
Kalibra Labs does not currently supply Dihexa. This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Who developed dihexa?
Dihexa was developed by Joseph Harding, John Wright and colleagues at Washington State University, with a patent priority date of 2011 and a detailed paper in 2013 [1, 3].
Is dihexa a peptide?
It is a heavily modified dipeptide: a tyrosine–isoleucine core with non-amino-acid caps on both ends, derived from the hexapeptide angiotensin IV [3].
Sources
- Harding JW, Wright JW, Benoist CC, Kawas LH, Wayman GA (Washington State University). Hepatocyte growth factor mimics as therapeutic agents. US Patent 8,598,118; priority 2 Apr 2011, granted 3 Dec 2013. Link
- Retraction Watch. Four papers by Athira CEO earn expressions of concern. 24 Sep 2021. Link
- McCoy AT, Benoist CC, Wright JW, et al., Harding JW. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141–154. doi:10.1124/jpet.112.199497. Link
- Benoist CC, Kawas LH, Zhu M, et al., Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014;351(2):390–402. doi:10.1124/jpet.114.218735. (Retracted.) Link
- Editors, J Pharmacol Exp Ther. Notice of concern regarding Benoist CC et al. 2014 (351:390–402). J Pharmacol Exp Ther. 2021;378(3):311. Link
- PubMed record PMID 25187433 (Benoist et al. 2014), marked retracted; retraction notice PMID 40312093 (2025). Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
- Holland & Knight. Peptides at a crossroads: what wellness providers need to know about HHS and FDA actions. 16 Oct 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
